The Diagnostic Technology Applied Research of CDK5RAP2 in Breast Cancer
The Diagnostic Technology Applied Research of CDK5RAP2 in Breast Cancer
Selected 400 cases of women with primary breast cancer who were treated with operation
 randomly, then detect the expression of CDK5RAP2 of cancer tissue. At the same time randomly
 selected 100 women with primary breast cancer who were under neoadjuvant chemotherapy. Detect
 the expression of CDK5RAP2 before and after neoadjuvant chemotherapy.
The investigators selected 400 cases of women with primary breast cancer who were treated
 with operation randomly,then detect the expression of CDK5RAP2 of cancer tissue. At the same
 time randomly selected 100 women with primary breast cancer who were under neoadjuvant
 chemotherapy. Detect the expression of CDK5RAP2 before and after neoadjuvant chemotherapy.
Inclusion Criteria:

 1. Provision of informed consent

 2. Pathological confirmation of breast cancer

 3. Tumor stage(TNM):T2-4bN0-3M0

 4. ER(+) and/or PR(+).

 5. Premenopausal woman.

 6. Age≥40 years

 7. Measurable disease as per RECIST criteria

 8. Karnofsky≥70

 9. Laboratory criteria:

 -  PLT≥100*109/L

 -  WBC≥4000/mm3

 -  HGB≥10g/dl

 -  ALT and AST<2*ULN

 Exclusion Criteria:

 1. Presence of metastatic disease.

 2. Inflammatory breast cancer.

 3. Bilateral breast cancer.

 4. previous chemotherapy or hormonal therapy for current breast neoplasm.

 5. other malignant tumor (concurrent or previous).

 6. Pregnant woman.

 7. Hypersensitive to any drug in CEF regimen or any ingredient of Zoladex.

 8. Any severe systemic disease contraindicating chemotherapy.